Compare Mondaycom Ltd (MNDY) vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mondaycom Ltd vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) — how do they compare? Mondaycom Ltd trades at $88.3 (market cap $3.76B), while Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.72 (market cap $58.74B). The key difference: Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) is far larger — about 15.6× Mondaycom Ltd's market cap, and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) pays a 3.33% dividend while Mondaycom Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mondaycom Ltd for 16 Days and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 1 Days on average.
| MNDY | TAK | |
|---|---|---|
Market Cap | $3.76B | $58.74B |
Volume | 836,200 | 3,110,994 |
Sector | Technology | Health |
52-Week High | $205.24 | $19.05 |
52-Week Low | $58.81 | $13.23 |
Typical Hold Time | 16 Days | 1 Days |
Enterprise Value | $2.92B | $86.65B |
Dividend Yield | — | 3.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Monday.com (MNDY) is trading at $89.50, up 7.17% with strong momentum following consecutive earnings beats. The stock shows bullish technical signals with support at $86 and resistance at $90. Fundamentally, the company maintains robust revenue growth ($1.23B in 2025) and high gross margins (88.74%), though valuation multiples remain elevated with P/E at 37.69. Recent news highlights strong enterprise client growth and AI integration initiatives at the upcoming Elevate '26 conference.
The outlook remains positive with 65% analyst buy ratings and a $108.64 consensus target, representing 21% upside. Key risks include competitive pressure from Meta's enterprise push and elevated valuation sensitivity. Earnings momentum and enterprise expansion provide catalysts, but investors should monitor Q3 2026 results against the $1.37 EPS expectation for sustained growth validation.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mondaycom Ltd
Monday.com Ltd. is a cloud-based software company providing a Work OS (Operating System) that enables organizations to manage projects, processes, and daily work. The platform is highly customizable, enabling teams to build tailored applications and workflows for a range of use cases, from marketing and sales to software development and HR. monday.com serves clients across numerous industries, aiming to improve transparency, collaboration, and efficiency across the entire enterprise.
Read more on MNDY →About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →
